StonvexLoading…
StonvexStonvexStonvexCore line items from IVZ's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $6.38B | $6.07B | $5.72B | $6.05B |
Operating Income | $-695.70M | $832.10M | $-434.80M | $1.32B |
Net Income | $-174.80M | $538.00M | $-333.70M | $683.90M |
EPS (Diluted) | $-1.60 | $1.18 | $-0.73 | $1.49 |
Total Assets | $27.09B | $27.01B | $28.93B | $29.76B |
Total Liabilities | $14.09B | $11.34B | $13.02B | $12.91B |
Cash & Equivalents | $1.04B | $986.50M | $1.47B | $1.23B |
Free Cash Flow OCF − CapEx | $1.44B | $1.12B | $1.14B | $510.30M |
Shares Outstanding | 444.00M | 448.00M | 449.50M | 454.80M |